Skip to main content

Table 2 Co-occurring Alzheimer’s disease pathology and clinicopathological correlation, hippocampal neuronal loss, and apolipoprotein E genotype

From: Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family

Identifier

Montine

Thal

Braak

CERAD

Correlation

Hippocampal neuronal loss

ApoE genotype

DR2.3

A1B1C1

2

2

1

Low

2

Ɛ2/Ɛ3

DR8.1

A0B1C0

0

1

0

Not

2

Ɛ3/Ɛ3

DR25.1

A0B1C0

0

1

0

Not

1

Ɛ3/Ɛ3

DR25.5

A0B1C0

0

1

0

Not

2

Ɛ3/Ɛ3

DR28.1

A3B1C1

5

1

1

Low

0

Ɛ3/Ɛ4

DR205.1

A2B1C1

3

2

1

Low

1

Ɛ2/Ɛ4

DR31.1

A1B1C1

2

1

1

Low

1

Ɛ2/Ɛ3

DR1207.1

A0B1C0

0

1

0

Not

1

Ɛ3/Ɛ3

DR1213.1

A0B1C0

0

1

0

Not

2

Ɛ3/Ɛ3

  1. ApoE Apolipoprotein E, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
  2. Column 2: Montine classification [39, 83]; column 3: Thal stages for β-amyloid plaques [84]; column 4: Braak stages for neurofibrillary changes [85]; column 5: CERAD stages for senile plaques [86]: 0 = no pathology, 1 = sparse CERAD score; column 6: clinicopathological correlation of Alzheimer’s disease neuropathological changes [39]; column 7: neuronal loss in hippocampal CA1 (scale 0–3): 0 = no pathology, 1 = mild neuronal loss, 2 = moderate neuronal loss; column 8: ApoE genotype
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193